In situ gastric floating gel of atazanavir sulphate for sustained release : formulation, optimization and evaluation
Aim: Atazanavir sulphate belongs to BCS class II drug, its oral bioavailability is limited due to its rapid first-pass metabolism and P-gp efflux. Materials & methods: The in situ floating gel using the complexed drug was prepared by ion gelation method and optimized the formulation as per 32 full factorial design. Results: Floating lag time of optimized formulation was found to be 18 s and percentage drug release of 94.18 ± 0.18 % at the end of 16 h. The concentration of gelling polymer affects drug release and a floating lag time and vice versa. Conclusion: In situ floating gel of atazanavir sulphate was found promising to sustain drug release due to an increased gastric residence time, which leads to enhanced potential therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 14(2023), 10 vom: 01. Okt., Seite 619-633 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Masareddy, Rajashree [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
β-cyclodextrin complex |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 09.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2023-0037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365451606 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365451606 | ||
| 003 | DE-627 | ||
| 005 | 20240209232005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2023-0037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM365451606 | ||
| 035 | |a (NLM)38054237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Masareddy, Rajashree |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In situ gastric floating gel of atazanavir sulphate for sustained release |b formulation, optimization and evaluation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Atazanavir sulphate belongs to BCS class II drug, its oral bioavailability is limited due to its rapid first-pass metabolism and P-gp efflux. Materials & methods: The in situ floating gel using the complexed drug was prepared by ion gelation method and optimized the formulation as per 32 full factorial design. Results: Floating lag time of optimized formulation was found to be 18 s and percentage drug release of 94.18 ± 0.18 % at the end of 16 h. The concentration of gelling polymer affects drug release and a floating lag time and vice versa. Conclusion: In situ floating gel of atazanavir sulphate was found promising to sustain drug release due to an increased gastric residence time, which leads to enhanced potential therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a atazanavir sulphate | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a in situ floating gel | |
| 650 | 4 | |a sustained drug delivery | |
| 650 | 4 | |a β-cyclodextrin complex | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Atazanavir Sulfate |2 NLM | |
| 650 | 7 | |a 4MT4VIE29P |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 650 | 7 | |a Gels |2 NLM | |
| 700 | 1 | |a Sandure, Pradnya |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Gaude, Yadishma |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Arpana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 14(2023), 10 vom: 01. Okt., Seite 619-633 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:619-633 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2023-0037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 10 |b 01 |c 10 |h 619-633 | ||